What does Capricor do and what are its main business segments?

Did Capricor beat or miss consensus estimates last quarter?

What guidance did Capricor's management provide for the next earnings period?

What is Capricor's gross profit margin?

What factors drove the changes in Capricor's revenue and profit?

What is the revenue and EPS growth rate for Capricor year over year?

What were the key takeaways from Capricor’s earnings call?

What were the key takeaways from Capricor's earnings call?

- **HOPE-3 Trial Milestone**: Deramiocel Phase III data unblinding imminent, targeting PUL 2.0 and LVEF endpoints. FDA Type 2 submission with 6-month review period. 
- **Manufacturing Readiness**: Cohort B evaluates commercial-scale production; facility passed FDA pre-license inspection. 
- **Financial Resilience**: $98.6 million cash; R&D expenses up 66% Y/Y due to HOPE-3. 
- **FDA Flexibility**: Agency may consider totality of evidence if primary endpoint missed. 
- **Exosome Platform**: COVID-19 vaccine trial data expected Q1 2026; potential for multivalent vaccines. 
- **Label Expansion**: Skeletal muscle indication contingent on PDUFA outcome. 
- **Regulatory Strategy**: Focus on cardiomyopathy approval first; Cohort B data critical for commercial manufacturing comparability.

**【CEO Summary Section】**
- Presented HOPE-3 Phase III trial results for deramiocel in Duchenne muscular dystrophy (DMD), with 105 patients across 20 clinical centers. Trial powered to detect changes in upper limb function (PUL 2.0) and left ventricular ejection fraction (LVEF). Cohort B evaluates commercial-scale manufacturing efficacy. FDA comment period closed without feedback; data unblinding expected within weeks. 
- HOPE-3 designed to address FDA CRL requests for additional efficacy and safety data. Submission classified as Type 2, with potential 6-month review period. 
- Exosome platform progress: NIAID-sponsored COVID-19 vaccine trial ongoing, targeting native protein delivery without adjuvants. 

**【CFO Financial Commentary】**
- Cash position: $98.6 million as of Q3 2025, sufficient for operations into 2026. 
- R&D expenses: $54.4 million (first 3Q 2025) vs. $32.8 million (2024), driven by HOPE-3 trial costs. 
- Manufacturing readiness: San Diego facility passed pre-license inspection; commercial-scale production underway. 

**【Q&A Key Highlights】**
- Statistical Analysis Plan (SAP): Hochberg method preserves alpha for primary endpoint (PUL 2.0). FDA may exercise regulatory flexibility if primary endpoint missed but LVEF shows statistical significance. 
- Cohort B focus: Highlights commercial manufacturing comparability; powered at 80% vs. Cohort A's 90%. 
- MRI review process: Triple-blind adjudication by independent readers to ensure data integrity. 
- FDA interactions: Type A meeting in August 2025; agency emphasized totality of evidence review. 
- Exosome platform: NIAID trial expected to report data in Q1 2026; potential for multivalent vaccines. 
- Regulatory strategy: Prioritize cardiomyopathy indication; label expansion contingent on PDUFA outcome.

Capricor Therapeutics, Inc. (CAPR) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

CAPR

CAPR fundamentals

You can ask Aime